<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An. bras. dermatol.</journal-id>
      <journal-title-group>
        <journal-title>Anais brasileiros de dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23539010</article-id>
      <article-id pub-id-type="pmc">3699945</article-id>
      <article-id pub-id-type="doi">10.1590/S0365-05962013000100012</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Allopurinol in the treatment of acquired reactive perforating collagenosis<sup><xref ref-type="fn" rid="fn01">*</xref></sup></article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Alopurinol no tratamento de colagenose reativa perfurante adquirida</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Tilz</surname>
            <given-names>Hemma</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Becker</surname>
            <given-names>J&#xFC;rgen Christian</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Legat</surname>
            <given-names>Franz</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schettini</surname>
            <given-names>Antonio Pedro Mendes</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Inzinger</surname>
            <given-names>Martin</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Massone</surname>
            <given-names>Cesare</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">5</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label> MD, resident in dermatology - Department of Dermatology, Division of General Dermatology, Medical University of Graz &#x2013; Graz, Austria.
</aff>
      <aff id="aff2"><label>2</label> Professor - Director of Department of Dermatology, Division of General Dermatology, Medical University of Graz &#x2013; Graz, Austria.
</aff>
      <aff id="aff3"><label>3</label> Professor - Professor of Department of Dermatology, Division of General Dermatology, Medical University of Graz &#x2013; Graz, Austria
</aff>
      <aff id="aff4"><label>4</label> Master's degree in Tropical Pathology from the Federal University of Amazonas (Universidade Federal do Amazonas - UFAM); Dermatologist of the Alfredo da Matta Foundation (Funda&#xE7;&#xE3;o "Alfredo da Matta") &#x2013; Manaus (AM), Brazil.
</aff>
      <aff id="aff5"><label>5</label> Professor - Professor of Department of Dermatology, Division of General Dermatology, Medical University of Graz &#x2013; Graz, Austria.
</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Cesare Massone Department of Dermatology, Medical University of Graz Auenbruggerplatz 8 A-8036 Graz, Austria E-mail: <email>cesare.massone@gmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of interest: J.C.Becker: adboard and speakers bureau for Roche and Glaxo Smith Kline</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>1</issue>
      <fpage>94</fpage>
      <lpage>97</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.anaisdedermatologia.org.br">http://www.anaisdedermatologia.org.br</ext-link>
      <ext-link ext-link-type="uri" xlink:href="http://www.scielo.br/abd">http://www.scielo.br/abd</ext-link>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>1</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>08</day>
          <month>4</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Acquired reactive perforating collagenosis is a perforating dermatosis usually associated with different systemic diseases, mainly diabetes mellitus and/or chronic renal insufficiency. Different therapies have been tried but treatment is not standardized yet and remains a challenge. In the last few years, allopurinol has been reported as a good therapeutic option for acquired reactive perforating collagenosis. We describe the case of a 73-year-old man affected by acquired reactive perforating collagenosis associated with diabetes type 1 and chronic renal failure with secondary hyperparathyroidism. The patient was successfully treated with allopurinol 100mg once/day p.o..</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>A colagenose reativa perfurante adquirida pertence ao grupo das dermatoses perfurantes e frequentemente est&#xE1; associada com diferentes doen&#xE7;as sist&#xEA;micas, principalmente diabetes mellitus e/ou insufici&#xEA;ncia renal cr&#xF4;nica. Diferentes terap&#xEA;uticas t&#xEA;m sido utilizadas, mas o tratamento ainda &#xE9; um desafio, pois n&#xE3;o existe tratamento padronizado. Nos &#xFA;ltimos anos, alopurinol tem sido relatado como uma boa op&#xE7;&#xE3;o terap&#xEA;utica para colagenose reativa perfurante adquirida. Relatamos o caso de um paciente masculino, com 73 anos de idade, portador de colagenose reativa perfurante adquirida em associa&#xE7;&#xE3;o com diabetes tipo 1 e fal&#xEA;ncia renal cr&#xF4;nica com hiperparatireoidismo secund&#xE1;rio. O paciente foi eficazmente tratado com alopurinol na dose 100mg/dia, via oral.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Allopurinol</kwd>
        <kwd>Diabetes mellitus</kwd>
        <kwd>Prurigo</kwd>
        <kwd>Renal insufficiency, Chronic</kwd>
        <kwd>Kidney failure, chronic</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Reactive perforating collagenosis (RPC) was described by Mehregan et al. in 1967 and belongs to the spectrum of perforating dermatoses; an inherited form and an acquired variant are known.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> The former appears early in childhood and recurs once or twice per year. On the contrary, acquired RPC (ARPC) appears late in life and is associated with different systemic diseases. Diagnostic criteria of ARPC (Faver's criteria) are: onset of lesions after the age of 18 years; umbilicated papules or nodules with a central adherent keratotic plug; on histopathology, elimination of altered collagen through an epithelium-lined crater filled with keratin.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Skin lesions may be disseminated all over the body and itching very severe; treatment is not standardized yet and remains a challenge.<sup><xref ref-type="bibr" rid="r01">1</xref></sup>
</p>
      <p>In the last few years, allopurinol has been reported as a good therapeutic option for ARPC.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r06">6</xref></sup> We describe the case of a male patient successfully treated with allopurinol. </p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 73-year-old man was admitted with intensively pruritic multiple erythematous excoriated papules and nodules with a central adherent keratotic plug up to 20mm in diameter involving the whole integument. Pruritus had started 10 months before and subsequently there was onset of keratotic papules and nodules (<xref ref-type="fig" rid="f01">Figure 1</xref>). The patient had suffered from diabetes type 1 for 50 years, complicated with retinopathy, cardiopathy, chronic renal failure and, in the last 5 years, also with secondary hyperparathyroidism. Medication consisted of insulin, bisoprolol, clopidogrel, telmisartan, nicorandil, furosemide, calcium dobesilate and ranitidine. Laboratory tests showed elevated creatinine 1.72mg/dl (0.7-1.20), urea 106mg/dl (10-45), potassium 5.5 mmol/l (3.5-5.0), HbA1c 8.0% (4.3-5.9), parathormon 89.8pg/ml (15.0-65.0), lymphocytes with 12% (20-40.0); uric acid 6.1mg/dl (3.4-7.0) was within normal range. </p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p><bold>A, B, C, D.</bold> Multiple excoriated hyperkeratotic papules and nodules with central crust involving the whole integument</p>
        </caption>
        <graphic xlink:href="abd-88-0094-g01"/>
      </fig>
      <p>Histopathology showed irregular epidermal hyperplasia with hypergranulosis, orthokeratosis and a cup-shaped depression of the epidermis with parakeratotic material, debris and extruded basophilic collagen fibres at the bottom (<xref ref-type="fig" rid="f02">Figure 2</xref>). Fibrosis and a perivascular lymphoplasmacellular infiltrate were present in the dermis. </p>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p><bold>A.</bold> Acanthosis of the epidermis with hypergranulosis and ortho-parakeratosis. On the left side, cup-shaped depression of the epidermis with parakeratotic material and debris. In the dermis fibrosis, teleangiectatis vessels and aspecific lymphohistiocytic infiltrate. <bold>B.</bold> Cup-shaped depression of the epidermis which is filled by parakeratotic keratin and neutrophils. At the bottom basophilic collagen fibres in vertical orientation that are extruded</p>
        </caption>
        <graphic xlink:href="abd-88-0094-g02"/>
      </fig>
      <p>The diagnosis of ARPC was made. The patient was initially given a 2-week course of antihistamines p.o.. Topically applied corticosteroids and 6-week narrow-band ultraviolet-B phototherapy were also tried. As pruritus and skin lesions persisted, allopurinol 100mg once/day p.o. was started. Skin lesions and pruritus improved within 4 weeks, in fact the lesions resolved to postinflammatory hyperpigmentations. Clinical response was maintained at 14-month follow-up visit with uninterrupted well-tolerated allopurinol therapy (<xref ref-type="fig" rid="f03">Figure 3</xref>). </p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p><bold>A, B, C, D.</bold> Multiple postinflammatory hyperpigmentations involving the whole integument after 8 months of treatment</p>
        </caption>
        <graphic xlink:href="abd-88-0094-g03"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>About one hundred ARPC cases have been reported in the English literature and ARPC has been observed mainly in patients with diabetes mellitus and/or chronic renal insufficiency, but it has been associated also with other endocrine disorders like hypothyroidism and hyperparathyroidism, liver dysfunction, sclerosing cholangitis, lung fibrosis, AIDS, pulmonary aspergillosis, scabies infection, leukemia, lymphoma and different malignancies.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> The pathogenesis is unknown. It has been hypothesized that mild superficial trauma (i.e. due to scratching) in patients with inherited susceptibility may lead to necrosis of papillary dermal collagen.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Diabetic vasculopathy and hypoxic conditions as insufficient small blood vessels supply may be aggravating factors.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Immunohisochemical and ultrastructural studies have shown that the extruded collagen is normal.<sup><xref ref-type="bibr" rid="r07">7</xref></sup> Using immunofluorescence techniques, Herzinger et al. demonstrated the presence of collagens type IV and type VII within the keratin plug, and suggested that collagen IV may elicit an immune response that triggers its penetration through the epidermis.<sup><xref ref-type="bibr" rid="r08">8</xref></sup>
</p>
      <p>The typical umbilicated (secondarily crateriform) papules or nodules can be localized only on the trunk or extremities or can be diffuse involving the all integument. Lesions are usually very itchy and new lesions can appear as a Koebner's phenomenon due to continuous scratching. However, pruritus is a common symptom in most systemic diseases associated which ARPC, thus it is not clear whether ARPC is a primary condition or a reaction to scratching. </p>
      <p>Histopathologic features depends on the evolution of the lesion. Early lesions shows epidermal acanthosis and accumulation of basophilic collagen in papillary dermis. Fully developed lesions show a dome-shaped epidermal depression (crater) filled with a parakeratotic plug, collagen and debris. Vertically oriented basophilic collagen fibres are extruded. Follicular involvement is present in 40% of cases.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r07">7</xref>-<xref ref-type="bibr" rid="r10">10</xref></sup>
</p>
      <p>Differential diagnosis includes mainly other perforating dermatoses like perforating folliculitis, elastosis perforans serpigininosa, Kyrle's disease, perforating calcifying elastosis and perforating granuloma annulare. More than 100 cases of APRC have been reported, 18 (18%) in the 70-79 year group like our patient.<sup><xref ref-type="bibr" rid="r01">1</xref></sup>
</p>
      <p>Treatment is difficult. ARPC usually improves when the coexisting systemic disease is treated. Numerous therapies have been tried in ARPC, including topical therapies like topical steroids, topical retinoic acid, phototherapy and systemic therapies like doxycycline, rifampicin and systemic retinoids. Still, no standard therapy is available.<sup><xref ref-type="bibr" rid="r01">1</xref></sup>
</p>
      <p>In some patients, allopurinol confirmed to be a valid and effective treatment.<sup><xref ref-type="bibr" rid="r02">2</xref>-<xref ref-type="bibr" rid="r06">6</xref></sup> The exact mechanism of action is unknown; it has been speculated that allopurinol inhibits xanthine oxidase which decreases oxygen free radicals that cause collagen damage and might inhibit collagen cross-linking by advanced glycation endproducts due to an antioxidative effect.<sup><xref ref-type="bibr" rid="r02">2</xref>-<xref ref-type="bibr" rid="r04">4</xref></sup> To our knowledge, only twelve patients (M:F=6:6; median age: 66,5; mean age: 67,6; range: 37-96) have been reported as effectively treated with allopurinol.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r06">6</xref></sup> ARPC was associated with diabetes and renal insufficiency in 4 patients, with only diabetes in 4 and renal insufficiency in 2. Uric acid was within normal range in 8 patients. Allopurinol, 100mg/day p.o., was started in all patients; in one of them, however, the daily dose had to be increased up to 300mg and in another was reduced to 50mg/day. Improvement was noticed already within one and 4 weeks in 7 patients and within 24 months in 5 patients.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r06">6</xref></sup>
</p>
      <p>Our experience supported by the literature suggests that allopurinol is a valid and effective treatment in patients with ARPC. Due to the rarity of ARPC, case series are difficult to collect but case reports should be encouraged including those in which allopurinol proved to be ineffective.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
      <fn id="fn01" fn-type="other">
        <p>* Study carried out at the Medical University of Graz - Graz, Austria.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karpouzis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giatromanolaki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sivridis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kouskoukis</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Acquired reactive perforating collagenosis: current status</article-title>
          <source>J Dermatol</source>
          <year>2010</year>
          <volume>37</volume>
          <fpage>585</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">20629824</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoque</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Ameen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Holden</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Acquired reactive perforating collagenosis: four patients with a giant variant treated with allopurinol</article-title>
          <source>Br J Dermatol</source>
          <year>2006</year>
          <volume>154</volume>
          <fpage>759</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="pmid">16536825</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gnanaraj</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Venugopal</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sangitha</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rajagopalan</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pandurangan</surname>
              <given-names>CN</given-names>
            </name>
          </person-group>
          <article-title>A giant variant of acquired reactive perforating collagenosis associated with hydronephrosis: successful treatment with allopurinol</article-title>
          <source>Int J Dermatol</source>
          <year>2009</year>
          <volume>48</volume>
          <fpage>204</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">19200207</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Querings</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Balda</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Bachter</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Treatment of acquired reactive perforating collagenosis with allopurinol</article-title>
          <source>Br J Dermatol</source>
          <year>2001</year>
          <volume>145</volume>
          <fpage>174</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">11453935</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iyoda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kuroki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kitazawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sugisaki</surname>
              <given-names>T</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Acquired reactive perforating collagenosis in a nondiabetic hemodialysis patient: successful treatment with allopurinol</article-title>
          <source>Am J Kidney Dis</source>
          <year>2003</year>
          <volume>42</volume>
          <fpage>E11</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">12955705</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kr&#xFC;ger</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tebbe</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Krengel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Goerdt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Orfanos</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Acquired reactive perforating dermatosis. Successful treatment with allopurinol in 2 cases</article-title>
          <source>Hautarzt</source>
          <year>1999</year>
          <volume>50</volume>
          <fpage>115</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">10097954</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Weedon</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <source>Skin Pathology</source>
          <edition>3rd ed</edition>
          <publisher-loc>London (UK)</publisher-loc>
          <publisher-name>Churchill Livingstone</publisher-name>
          <year>2010</year>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herzinger</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schirren</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Sander</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Jansen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kind</surname>
              <given-names>P. A</given-names>
            </name>
          </person-group>
          <article-title>Reactive perforating collagenosis - transepidermal elimination of type IV collagen</article-title>
          <source>Clin Exp Dermatol</source>
          <year>1996</year>
          <volume>21</volume>
          <fpage>279</fpage>
          <lpage>282</lpage>
          <pub-id pub-id-type="pmid">8959899</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Castro</surname>
              <given-names>LGM</given-names>
            </name>
            <name>
              <surname>Nogueira</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Valente</surname>
              <given-names>NYS</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">Colagenose reativa perfurante adquirida associada a insufici&#xEA;ncia card&#xED;aca congestiva</article-title>
          <source>An Bras Dermatol</source>
          <year>2001</year>
          <volume>76</volume>
          <fpage>437</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Badziak</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lenhardt</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>de Barros</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Mandelli</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Serafini</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>Santamaria</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">Dermatose perfurante adquirida associada &#xE0; insufici&#xEA;ncia hep&#xE1;tica em paciente transplantado de f&#xED;gado</article-title>
          <source>An Bras Dermatol</source>
          <year>2007</year>
          <volume>82</volume>
          <fpage>53</fpage>
          <lpage>6</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
